HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
Clinical trial NCT05621499 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05621499
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-20
- Primary completion
- 2026-11-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.